MedTrace Logo

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

NCT05609903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2022-11-08

No results posted yet for this study

Summary

The study will evaluate the therapeutic efficacy of the association of Atezolizumab plus nabPaclitaxel in a real life context, in order to document any differences both in terms of activity and safety with respect to the knowledge of the association reported in the literature

Conditions

  • Breast Cancer Metastatic

Interventions

DRUG

Atezolizumab in combination with nab-paclitaxel

Treatment of patients with stage IV triple negative breast cancer with Atezolizumab in combination with nab-paclitaxel

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • Alessandra Fabi · Policlinico A. Gemelli

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-08-01
Completion
2022-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05609903 on ClinicalTrials.gov